BLOG

endpoints

Has Selecta found a way around gene therapy’s delivery problem? Takeda puts down $1B-plus to find out

Selecta’s platform makes use of a biodegradable nanoparticle that encapsulates the immunosuppressive drug rapamycin, and is designed to be given in conjunction with gene therapies to induce antigen-specific immune tolerance.